EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

Haticegul Tuncer, Semih Ergisi, Hasan Volkan Ege, Murat Gultekin, Zafer Selcuk Tuncer, Derman Basaran

Cancers · 19.11.2026 · 18 (22) · 3702

DOI: 10.3390/cancers18223702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 19.11.2026. Verfasst von Haticegul Tuncer und 5 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Venous thromboembolism is common during neoadjuvant chemotherapy for advanced ovarian cancer, but when to start thromboprophylaxis is unclear. We evaluated the association between early prophylactic-dose low-molecular-weight heparin, started at diagnosis or before the first cycle, and venous thromboembolism during neoadjuvant chemotherapy.

Methods

This retrospective single-center cohort study included all consecutive women with stage III–IV epithelial ovarian cancer diagnosed between September 2012 and January 2025 who received neoadjuvant chemotherapy. Patients with venous thromboembolism at diagnosis were excluded. The primary endpoint was confirmed venous thromboembolism from the first cycle until interval debulking surgery or, without surgery, until completion of planned neoadjuvant chemotherapy or day 120, whichever occurred first. Associations were explored with Firth-penalized logistic regression.

Results

Of 201 patients who received neoadjuvant chemotherapy, 192 formed the analytic cohort; 148 (77.1%) received early prophylaxis. Primary endpoint events occurred in 7 patients (3.6%; six pulmonary embolisms) at a median of 3.1 weeks after diagnosis. Events occurred in 1 of 148 patients (0.7%) with early prophylaxis and 6 of 44 (13.6%) without it. In exploratory multivariable analysis, early prophylaxis remained associated with lower odds (adjusted odds ratio [OR] 0.08, 95% confidence interval [CI] 0.01–0.47). A Khorana score of 3 or higher was associated with higher, imprecisely estimated odds (adjusted OR 12.70, 95% CI 1.17–1722). No major or clinically relevant non-major bleeding was identified (0/148 with prophylaxis; 95% CI 0–2.46%).

Conclusions

Early prophylactic-dose low-molecular-weight heparin was associated with fewer venous thromboembolic events during neoadjuvant chemotherapy. Because prophylaxis was not randomized and events were few, these hypothesis-generating findings require prospective validation.

Zitieren

APA

Tuncer, H., Ergisi, S., Ege, H. V., Gultekin, M., Tuncer, Z. S., & Basaran, D. (2026). Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. Cancers, 18(22), 3702. https://doi.org/10.3390/cancers18223702

Vancouver

Tuncer H, Ergisi S, Ege HV, Gultekin M, Tuncer ZS, Basaran D. Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. Cancers. 2026;18(22):3702. doi:10.3390/cancers18223702

BibTeX
@article{Tuncer2026,
  author = {Tuncer, Haticegul and Ergisi, Semih and Ege, Hasan Volkan and Gultekin, Murat and Tuncer, Zafer Selcuk and Basaran, Derman},
  title = {Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3702},
  doi = {10.3390/cancers18223702}
}
Kostenlos starten →